TheraRadar
Data updated: May 26, 2026

SUPRAX (cefixime)

Trial Activity: Declining
Infectious Disease Approved 1989-04-28

SUPRAX is indicated for the treatment of Urinary Tract Infection; Otitis Media; Pharyngitis; Tonsillitis; Chronic Bronchitis; Gonorrhea.

Source: FDA Label • Lupin

How SUPRAX Works

Cefixime is a semisynthetic, third-generation cephalosporin that exerts bactericidal activity by inhibiting bacterial cell wall synthesis. It binds to specific penicillin-binding proteins

Development Insights

National Institute of Allergy and Infectious Diseases (NIAID) conducting 5 trials (56%)
9 indications explored (Moderate)
gonorrhoea (2 trials)
gonorrhea male (1 trials)
typhoid fever (1 trials)
9
Indications
--
Phase 3 Trials
37
Years on Market

Details

Status
Discontinued
First Approved
1989-04-28
Patent Cliff
2028

Pro Metrics

Patent cliff and revenue data

Unlock with Pro
Routes
ORAL
Dosage Forms
TABLET, CAPSULE, FOR SUSPENSION, TABLET, CHEWABLE

Companies

Active Ingredient: CEFIXIME

SUPRAX Approval History

1990
1991
1992
1993
1994
1995
1996
1997
1998
1999
2000
2001
2002
2003
2004
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
Original
New Indication
New Form
Label Update
115 FDA actions from 1989 to 2025 · 1 indication expansions
May 2025 SUPPL
Label · Labeling
Oct 2019 SUPPL
Label · Labeling
Jun 2018 SUPPL
Mfg · Manufacturing (CMC)

What SUPRAX Treats

6 indications

SUPRAX is approved for 6 conditions since its original approval in 1989. These indications span multiple therapeutic areas including oncology, immunology, and more.

  • Urinary Tract Infection
  • Otitis Media
  • Pharyngitis
  • Tonsillitis
  • Chronic Bronchitis
  • Gonorrhea
Source: FDA Label

SUPRAX Competitive Set

Pro

Three rings of competition based on shared molecular targets and treated indications.

Unlock 8 more competitors across all three rings.
Upgrade to Pro

Filters applied: drops same-active-ingredient (505(b)(2) reformulations), route-mismatch (topical vs systemic), and cross-therapeutic-area matches in same-indication rings.

Drugs Similar to SUPRAX

3 of 20

FDA-approved drugs for similar conditions. Compare mechanisms and indications to understand treatment alternatives.

CEFUROXIME AXETIL
CEFUROXIME AXETIL
4 shared
Lupin
Shared indications:
PharyngitisTonsillitisUrinary Tract Infection +1 more
AZITHROMYCIN
AZITHROMYCIN
2 shared
Sun Pharma
Shared indications:
PharyngitisTonsillitis
CEFPODOXIME PROXETIL
CEFPODOXIME PROXETIL
2 shared
ANDA REPOSITORY
Shared indications:
PharyngitisTonsillitis
📋

Clinical Trial Registry

9 trials
Trial Sponsor ID Phase Status Title
NCT05294588 21-0498 DMID 21-0018, U01AI162457-01 Ph 2 completed Efficacy of Immunization With 4C-MenB in Preventing Experimental Urethral Infection With Neisseria Gonorrhoeae
NCT04349826 ACT-South Asia 25NP Ph 4 completed The Azithromycin and Cefixime Treatment of Typhoid in South Asia Trial (ACT-South Asia Trial)
NCT06090565 9937 Ph 4 completed Cefixime Plus Doxycycline Compared to Ceftriaxone Plus Azithromycin for Treatment of Gonorrhoea
NCT03840811 results posted 09-0106 Ph 1 completed Experimental Human Infection With Neisseria Gonorrhoeae
NCT00786669 VITAC VITAC Ph 1 completed A Pilot Study of the Addition of Bevacizumab to VOIT Regimen for Relapsed/Refractory Pediatric Solid Tumors
NCT01595529 results posted 09-0103 Ph 2 completed The SCOUT Study: "Short Course Therapy for Urinary Tract Infections in Children"
NCT01949363 12-0025 HHSN272201500007I Ph 1 completed The Pharmacokinetics of Extended Duration High-dose Cefixime for the Decreased Susceptibility of Neisseria Gonorrhoeae: A Phase I Pilot Study
NCT02708992 15-0031 HHSN272201500006I Ph 1 completed Cefixime / Azithromycin pK Study
NCT01072136 results posted 07-0082 Ph 3 terminated Empiric Therapy of Mucopurulent Cervicitis (MPC)
🔬

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
📊

Trial Timeline

Full development history with FDA approval milestones

|
Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

SUPRAX FDA Label Details

Indications & Usage

FDA Label (PDF)

SUPRAX is indicated for the treatment of Urinary Tract Infection; Otitis Media; Pharyngitis; Tonsillitis; Chronic Bronchitis; Gonorrhea.

View full patent landscape →
1 OB patents · 1 families · 2 international docs across 1 countries

SUPRAX Patents & Exclusivity

Latest Patent: Dec 2028

Patents (1 active)

US9233112 Expires Dec 14, 2028
Source: FDA Orange Book

Pro Intelligence Preview

Deep insights for SUPRAX

Revenue Insights

  • Quarterly revenue tracking
  • Historical trend analysis

Patent Timeline

  • Cliff: 2028
  • 1 active patents

Trial Analysis

  • 9 total trials
  • Stage: Declining

Competitive Landscape

  • 20 similar drugs
  • Same target/indication analysis
Unlock Full Intelligence

Full approval history • All patents • Revenue trends • Competitor analysis

Data Sources

Data sourced from official FDA and NIH databases. Click links to verify on original sources.

How We Calculate These Metrics

Trial Activity Stage

Measures the current development activity pattern based on trial phases, status, and trends. Important: This measures R&D activity, not commercial lifecycle.

Trial statuses: "Active" means recruiting or ongoing. "Completed" means reached planned endpoint. "Terminated" means stopped early—often due to safety, efficacy, or business reasons.

  • Growth: High proportion of early-phase trials (Phase 1/2), active development
  • Expansion: Significant Phase 3 activity, approaching or pursuing approvals
  • Mature: Substantial Phase 4 post-marketing studies
  • Stable: Mixed phase distribution, steady development
  • Declining: Low active trial ratio, reduced R&D investment